Respiratory Virus Infection Drug Market: Global Industry Analysis and forecast 2019 – 2027: By Disease Type, Applications, Drug Class, and Region.

Respiratory Virus Infection Drug Market value is projected to reach US$ 66.82 Bn at the end of the forecast period and it is expected to grow at the CAGR of 7.1%. The viral infections, such as human immunodeficiency virus (HIV), hepatitis, and influenza are treated by antiviral drugs. Various antiviral drugs can be used to treat viral infections. Several investigational drugs for the treatment of HIV infection are currently in the process of manufacturing in many pharmaceutical companies. Increasing rate of HIV infections is likely to drive the demand for antiviral drugs. To know about the Research Methodology :- Request Free Sample Report The growth of respiratory virus infection drug market is projected to get increased due to the Increasing number of patients and the rise in the birth rate. As per the data published by United Nations, Department of Economic and Social Affairs, the global population is estimated to reach 8.5 billion by 2030. The drivers of the market are mainly increasing incidences of respiratory infections and technological advancements for example, use of nanotechnology in virology also the potential for antiviral therapeutics, and growing demand for good quality of healthcare. North America is expected to continue to hold the largest XX.XX% share in Respiratory Virus Infection Drug Market and Europe holds the second-largest share in the Respiratory Virus Infection Drug Market . It is due to more awareness and easy availability of diagnostic tests. According to the data published by the U.S., Department of Health & Human Services, about 50% of the children infected with Respiratory virus infection were under two-years of the age. Asia Pacific region is forecasted to be the fastest growing market in forecast period. Respiratory Virus Infection Drug Markets in Japan and India are also expected to show a significant growth during the forecast period. The rise in the number of patients, increasing income of middle-class people , flow in the health insurance market, and increased awareness about good quality of healthcare. The objective of the report is to present a comprehensive analysis of the Respiratory Virus Infection Drug Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Respiratory Virus Infection Drug Market dynamics, structure by analyzing the market segments and projects the Respiratory Virus Infection Drug Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Respiratory Virus Infection Drug Market make the report investor’s guide.

Scope of the Respiratory Virus Infection Drug Market: Inquire before buying

Respiratory Virus Infection Drug Market, By Disease Type

• Upper Respiratory Tract Infections (URTIs) • Influenza • Bronchiolitis • Croup • Pneumonia • Measles • Others

Respiratory Virus Infection Drug Market, By Drug Class

• Nucleoside Analogs • Neuraminidase Inhibitors • Ion Channel Blockers • Fusion Protein Inhibitors

Respiratory Virus Infection Drug Market, By Region

• Asia Pacific • North America • Europe • South America • Middle East & Africa

Key players operating in the Respiratory Virus Infection Drug Market

• AstraZeneca • AbbVie • Ablynx NV • ADMA Biologics • Alnylam Pharmaceuticals • Ark Biosciences • ImmunoVaccine Technologies, • Aviragen Therapeutics • Boehringer Ingelheim • Bavarian Nordic • Gilead Sciences • Johnson & Johnson • Kyowa Hakko Kirin • Mymetics Corporation • GlaxoSmithKline plc. • Teva Pharmaceutical • Vaxart
Respiratory Virus Infection Drug Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Respiratory Virus Infection Drug Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Respiratory Virus Infection Drug Market Analysis and Forecast 6.1. Respiratory Virus Infection Drug Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Respiratory Virus Infection Drug Market Analysis and Forecast, By Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Respiratory Virus Infection Drug Market Value Share Analysis, By Drug Class 7.4. Respiratory Virus Infection Drug Market Size (US$ Bn) Forecast, By Drug Class 7.5. Respiratory Virus Infection Drug Market Analysis, By Drug Class 7.6. Respiratory Virus Infection Drug Market Attractiveness Analysis, By Drug Class 8. Respiratory Virus Infection Drug Market Analysis and Forecast, By Disease Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Respiratory Virus Infection Drug Market Value Share Analysis, By Disease Type 8.4. Respiratory Virus Infection Drug Market Size (US$ Bn) Forecast, By Disease Type 8.5. Respiratory Virus Infection Drug Market Analysis, By Disease Type 8.6. Respiratory Virus Infection Drug Market Attractiveness Analysis, By Disease Type 9. Respiratory Virus Infection Drug Market Analysis, by Region 9.1. Respiratory Virus Infection Drug Market Value Share Analysis, by Region 9.2. Respiratory Virus Infection Drug Market Size (US$ Bn) Forecast, by Region 9.3. Respiratory Virus Infection Drug Market Attractiveness Analysis, by Region 10. North America Respiratory Virus Infection Drug Market Analysis 10.1. Key Findings 10.2. North America Respiratory Virus Infection Drug Market Overview 10.3. North America Respiratory Virus Infection Drug Market Value Share Analysis, By Drug Class 10.4. North America Respiratory Virus Infection Drug Market Forecast, By Drug Class 10.4.1. Nucleoside Analogs 10.4.2. Neuraminidase Inhibitors 10.4.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 10.5. North America Respiratory Virus Infection Drug Market Value Share Analysis, By Disease Type 10.6. North America Respiratory Virus Infection Drug Market Forecast, By Disease Type 10.6.1. Upper Respiratory Tract Infections (URTIs) 10.6.2. Influenza 10.6.3. Bronchiolitis 10.6.4. Croup 10.6.5. Others(Pneumonia,Measles) 10.7. North America Respiratory Virus Infection Drug Market Value Share Analysis, by Country 10.8. North America Respiratory Virus Infection Drug Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Respiratory Virus Infection Drug Market Analysis, by Country 10.10. U.S. Respiratory Virus Infection Drug Market Forecast, By Drug Class 10.10.1. Nucleoside Analogs 10.10.2. Neuraminidase Inhibitors 10.10.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 10.11. U.S. Respiratory Virus Infection Drug Market Forecast, By Disease Type 10.11.1. Upper Respiratory Tract Infections (URTIs) 10.11.2. Influenza 10.11.3. Bronchiolitis 10.11.4. Croup 10.11.5. Others(Pneumonia,Measles) 10.12. Canada Respiratory Virus Infection Drug Market Forecast, By Drug Class 10.12.1. Nucleoside Analogs 10.12.2. Neuraminidase Inhibitors 10.12.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 10.13. Canada Respiratory Virus Infection Drug Market Forecast, By Disease Type 10.13.1. Upper Respiratory Tract Infections (URTIs) 10.13.2. Influenza 10.13.3. Bronchiolitis 10.13.4. Croup 10.13.5. Others(Pneumonia,Measles) 10.14. North America Respiratory Virus Infection Drug Market Attractiveness Analysis 10.14.1. By Drug Class 10.14.2. By Disease Type 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Developments 11. Europe Respiratory Virus Infection Drug Market Analysis 11.1. Key Findings 11.2. Europe Respiratory Virus Infection Drug Market Overview 11.3. Europe Respiratory Virus Infection Drug Market Value Share Analysis, By Drug Class 11.4. Europe Respiratory Virus Infection Drug Market Forecast, By Drug Class 11.4.1. Nucleoside Analogs 11.4.2. Neuraminidase Inhibitors 11.4.3. Others(Ion Channel Blockers, Fusion Protein Inhibitors) 11.5. Europe Respiratory Virus Infection Drug Market Value Share Analysis, By Disease Type 11.6. Europe Respiratory Virus Infection Drug Market Forecast, By Disease Type 11.6.1. Upper Respiratory Tract Infections (URTIs) 11.6.2. Influenza 11.6.3. Bronchiolitis 11.6.4. Croup 11.6.5. Others (Pneumonia,Measles) 11.7. Europe Respiratory Virus Infection Drug Market Value Share Analysis, by Country 11.8. Europe Respiratory Virus Infection Drug Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Norway 11.8.7. Russia 11.8.8. Rest of Europe 11.9. Europe Respiratory Virus Infection Drug Market Analysis, by Country 11.10. Germany Respiratory Virus Infection Drug Market Forecast, By Drug Class 11.10.1. Nucleoside Analogs 11.10.2. Neuraminidase Inhibitors 11.10.3. Others(Ion Channel Blockers, Fusion Protein Inhibitors) 11.11. Germany Respiratory Virus Infection Drug Market Forecast, By Disease Type 11.11.1. Upper Respiratory Tract Infections (URTIs) 11.11.2. Influenza 11.11.3. Bronchiolitis 11.11.4. Croup 11.11.5. Others(Pneumonia,Measles) 11.12. U.K. Respiratory Virus Infection Drug Market Forecast, By Drug Class 11.12.1. Nucleoside Analogs 11.12.2. Neuraminidase Inhibitors 11.12.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 11.13. U.K. Respiratory Virus Infection Drug Market Forecast, By Disease Type 11.13.1. Upper Respiratory Tract Infections (URTIs) 11.13.2. Influenza 11.13.3. Bronchiolitis 11.13.4. Croup 11.13.5. Others(Pneumonia,Measles) 11.14. France Respiratory Virus Infection Drug Market Forecast, By Drug Class 11.14.1. Nucleoside Analogs 11.14.2. Neuraminidase Inhibitors 11.14.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 11.15. France Respiratory Virus Infection Drug Market Forecast, By Disease Type 11.15.1. Upper Respiratory Tract Infections (URTIs) 11.15.2. Influenza 11.15.3. Bronchiolitis 11.15.4. Croup 11.15.5. Others(Pneumonia,Measles) 11.16. Italy Respiratory Virus Infection Drug Market Forecast, By Drug Class 11.16.1. Nucleoside Analogs 11.16.2. Neuraminidase Inhibitors 11.16.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 11.17. Italy Respiratory Virus Infection Drug Market Forecast, By Disease Type 11.17.1. Upper Respiratory Tract Infections (URTIs) 11.17.2. Influenza 11.17.3. Bronchiolitis 11.17.4. Croup 11.17.5. Others(Pneumonia,Measles) 11.18. Spain Respiratory Virus Infection Drug Market Forecast, By Drug Class 11.18.1. Nucleoside Analogs 11.18.2. Neuraminidase Inhibitors 11.18.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 11.19. Spain Respiratory Virus Infection Drug Market Forecast, By Disease Type 11.19.1. Upper Respiratory Tract Infections (URTIs) 11.19.2. Influenza 11.19.3. Bronchiolitis 11.19.4. Croup 11.19.5. Others(Pneumonia,Measles) 11.20. Norway Respiratory Virus Infection Drug Market Forecast, By Drug Class 11.20.1. Nucleoside Analogs 11.20.2. Neuraminidase Inhibitors 11.20.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 11.21. Norway Respiratory Virus Infection Drug Market Forecast, By Disease Type 11.21.1. Upper Respiratory Tract Infections (URTIs) 11.21.2. Influenza 11.21.3. Bronchiolitis 11.21.4. Croup 11.21.5. Others(Pneumonia,Measles) 11.22. Russia Respiratory Virus Infection Drug Market Forecast, By Drug Class 11.22.1. Nucleoside Analogs 11.22.2. Neuraminidase Inhibitors 11.22.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 11.23. Russia Respiratory Virus Infection Drug Market Forecast, By Disease Type 11.23.1. Upper Respiratory Tract Infections (URTIs) 11.23.2. Influenza 11.23.3. Bronchiolitis 11.23.4. Croup 11.23.5. Others(Pneumonia,Measles) 11.24. Rest of Europe Respiratory Virus Infection Drug Market Forecast, By Drug Class 11.24.1. Nucleoside Analogs 11.24.2. Neuraminidase Inhibitors 11.24.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 11.25. Rest of Europe Respiratory Virus Infection Drug Market Forecast, By Disease Type 11.25.1. Upper Respiratory Tract Infections (URTIs) 11.25.2. Influenza 11.25.3. Bronchiolitis 11.25.4. Croup 11.25.5. Others(Pneumonia,Measles) 11.26. Europe Respiratory Virus Infection Drug Market Attractiveness Analysis 11.26.1. By Drug Class 11.26.2. By Disease Type 11.27. PEST Analysis 11.28. Key Trends 11.29. Key Developments 12. Asia Pacific Respiratory Virus Infection Drug Market Analysis 12.1. Key Findings 12.2. Asia Pacific Respiratory Virus Infection Drug Market Overview 12.3. Asia Pacific Respiratory Virus Infection Drug Market Value Share Analysis, By Drug Class 12.4. Asia Pacific Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.4.1. Nucleoside Analogs 12.4.2. Neuraminidase Inhibitors 12.4.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.5. Asia Pacific Respiratory Virus Infection Drug Market Value Share Analysis, By Disease Type 12.6. Asia Pacific Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.6.1. Upper Respiratory Tract Infections (URTIs) 12.6.2. Influenza 12.6.3. Bronchiolitis 12.6.4. Croup 12.6.5. Others(Pneumonia,Measles) 12.7. Asia Pacific Respiratory Virus Infection Drug Market Value Share Analysis, by Country 12.8. Asia Pacific Respiratory Virus Infection Drug Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. Malaysia 12.8.7. Indonesia 12.8.8. Vietnam 12.8.9. Rest of Asia Pacific 12.9. Asia Pacific Respiratory Virus Infection Drug Market Analysis, by Country 12.10. China Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.10.1. Nucleoside Analogs 12.10.2. Neuraminidase Inhibitors 12.10.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.11. China Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.11.1. Upper Respiratory Tract Infections (URTIs) 12.11.2. Influenza 12.11.3. Bronchiolitis 12.11.4. Croup 12.11.5. Others(Pneumonia,Measles) 12.12. India Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.12.1. Nucleoside Analogs 12.12.2. Neuraminidase Inhibitors 12.12.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.13. India Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.13.1. Upper Respiratory Tract Infections (URTIs) 12.13.2. Influenza 12.13.3. Bronchiolitis 12.13.4. Croup 12.13.5. Others(Pneumonia,Measles) 12.14. Japan Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.14.1. Nucleoside Analogs 12.14.2. Neuraminidase Inhibitors 12.14.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.15. Japan Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.15.1. Upper Respiratory Tract Infections (URTIs) 12.15.2. Influenza 12.15.3. Bronchiolitis 12.15.4. Croup 12.15.5. Others(Pneumonia,Measles) 12.16. South Korea Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.16.1. Nucleoside Analogs 12.16.2. Neuraminidase Inhibitors 12.16.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.17. South Korea Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.17.1. Upper Respiratory Tract Infections (URTIs) 12.17.2. Influenza 12.17.3. Bronchiolitis 12.17.4. Croup 12.17.5. Others(Pneumonia,Measles) 12.18. Australia Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.18.1. Nucleoside Analogs 12.18.2. Neuraminidase Inhibitors 12.18.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.19. Australia Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.19.1. Upper Respiratory Tract Infections (URTIs) 12.19.2. Influenza 12.19.3. Bronchiolitis 12.19.4. Croup 12.19.5. Others(Pneumonia,Measles) 12.20. Malaysia Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.20.1. Nucleoside Analogs 12.20.2. Neuraminidase Inhibitors 12.20.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.21. Malaysia Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.21.1. Upper Respiratory Tract Infections (URTIs) 12.21.2. Influenza 12.21.3. Bronchiolitis 12.21.4. Croup 12.21.5. Others(Pneumonia,Measles) 12.22. Indonesia Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.22.1. Nucleoside Analogs 12.22.2. Neuraminidase Inhibitors 12.22.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.23. Indonesia Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.23.1. Upper Respiratory Tract Infections (URTIs) 12.23.2. Influenza 12.23.3. Bronchiolitis 12.23.4. Croup 12.23.5. Others(Pneumonia,Measles) 12.24. Vietnam Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.24.1. Nucleoside Analogs 12.24.2. Neuraminidase Inhibitors 12.24.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.25. Vietnam Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.25.1. Upper Respiratory Tract Infections (URTIs) 12.25.2. Influenza 12.25.3. Bronchiolitis 12.25.4. Croup 12.25.5. Others(Pneumonia,Measles) 12.26. Rest of Asia Pacific Respiratory Virus Infection Drug Market Forecast, By Drug Class 12.26.1. Nucleoside Analogs 12.26.2. Neuraminidase Inhibitors 12.26.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 12.27. Rest of Asia Pacific Respiratory Virus Infection Drug Market Forecast, By Disease Type 12.27.1. Retail Industry 12.27.2. Upper Respiratory Tract Infections (URTIs) 12.27.3. Influenza 12.27.4. Bronchiolitis 12.27.5. Croup 12.27.6. Others(Pneumonia,Measles) 12.28. Asia Pacific Respiratory Virus Infection Drug Market Attractiveness Analysis 12.28.1. By Drug Class 12.28.2. By Disease Type 12.29. PEST Analysis 12.30. Key Trends 12.31. Key Developments 13. Middle East & Africa Respiratory Virus Infection Drug Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Respiratory Virus Infection Drug Market Overview 13.3. Middle East & Africa Respiratory Virus Infection Drug Market Value Share Analysis, By Drug Class 13.4. Middle East & Africa Respiratory Virus Infection Drug Market Forecast, By Drug Class 13.4.1. Nucleoside Analogs 13.4.2. Neuraminidase Inhibitors 13.4.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 13.5. Middle East & Africa Respiratory Virus Infection Drug Market Value Share Analysis, By Disease Type 13.6. Middle East & Africa Respiratory Virus Infection Drug Market Forecast, By Disease Type 13.6.1. Upper Respiratory Tract Infections (URTIs) 13.6.2. Influenza 13.6.3. Bronchiolitis 13.6.4. Croup 13.6.5. Others(Pneumonia,Measles) 13.7. Middle East & Africa Respiratory Virus Infection Drug Market Value Share Analysis, by Country 13.8. Middle East & Africa Respiratory Virus Infection Drug Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Respiratory Virus Infection Drug Market Analysis, by Country 13.10. GCC Respiratory Virus Infection Drug Market Forecast, By Drug Class 13.10.1. Nucleoside Analogs 13.10.2. Neuraminidase Inhibitors 13.10.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 13.11. GCC Respiratory Virus Infection Drug Market Forecast, By Disease Type 13.11.1. Upper Respiratory Tract Infections (URTIs) 13.11.2. Influenza 13.11.3. Bronchiolitis 13.11.4. Croup 13.11.5. Others(Pneumonia,Measles) 13.12. South Africa Respiratory Virus Infection Drug Market Forecast, By Drug Class 13.12.1. Nucleoside Analogs 13.12.2. Neuraminidase Inhibitors 13.12.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 13.13. South Africa Respiratory Virus Infection Drug Market Forecast, By Disease Type 13.13.1. Upper Respiratory Tract Infections (URTIs) 13.13.2. Influenza 13.13.3. Bronchiolitis 13.13.4. Croup 13.13.5. Others(Pneumonia,Measles) 13.14. Rest of Middle East & Africa Respiratory Virus Infection Drug Market Forecast, By Drug Class 13.14.1. Nucleoside Analogs 13.14.2. Neuraminidase Inhibitors 13.14.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 13.15. Rest of Middle East & Africa Respiratory Virus Infection Drug Market Forecast, By Disease Type 13.15.1. Upper Respiratory Tract Infections (URTIs) 13.15.2. Influenza 13.15.3. Bronchiolitis 13.15.4. Croup 13.15.5. Others(Pneumonia,Measles) 13.16. Middle East & Africa Respiratory Virus Infection Drug Market Attractiveness Analysis 13.16.1. By Drug Class 13.16.2. By Disease Type 13.17. PEST Analysis 13.18. Key Trends 13.19. Key Developments 14. South America Respiratory Virus Infection Drug Market Analysis 14.1. Key Findings 14.2. South America Respiratory Virus Infection Drug Market Overview 14.3. South America Respiratory Virus Infection Drug Market Value Share Analysis, By Drug Class 14.4. South America Respiratory Virus Infection Drug Market Forecast, By Drug Class 14.4.1. Nucleoside Analogs 14.4.2. Neuraminidase Inhibitors 14.4.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 14.5. South America Respiratory Virus Infection Drug Market Value Share Analysis, By Disease Type 14.6. South America Respiratory Virus Infection Drug Market Forecast, By Disease Type 14.6.1. Upper Respiratory Tract Infections (URTIs) 14.6.2. Influenza 14.6.3. Bronchiolitis 14.6.4. Croup 14.6.5. Others(Pneumonia,Measles) 14.7. South America Respiratory Virus Infection Drug Market Value Share Analysis, by Country 14.8. South America Respiratory Virus Infection Drug Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America Respiratory Virus Infection Drug Market Analysis, by Country 14.10. Brazil Respiratory Virus Infection Drug Market Forecast, By Drug Class 14.10.1. Nucleoside Analogs 14.10.2. Neuraminidase Inhibitors 14.10.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 14.11. Brazil Respiratory Virus Infection Drug Market Forecast, By Disease Type 14.11.1. Upper Respiratory Tract Infections (URTIs) 14.11.2. Influenza 14.11.3. Bronchiolitis 14.11.4. Croup 14.11.5. Others(Pneumonia,Measles) 14.12. Mexico Respiratory Virus Infection Drug Market Forecast, By Drug Class 14.12.1. Nucleoside Analogs 14.12.2. Neuraminidase Inhibitors 14.12.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 14.13. Mexico Respiratory Virus Infection Drug Market Forecast, By Disease Type 14.13.1. Upper Respiratory Tract Infections (URTIs) 14.13.2. Influenza 14.13.3. Bronchiolitis 14.13.4. Croup 14.13.5. Others(Pneumonia,Measles) 14.14. Argentina Respiratory Virus Infection Drug Market Forecast, By Drug Class 14.14.1. Nucleoside Analogs 14.14.2. Neuraminidase Inhibitors 14.14.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 14.15. Argentina Respiratory Virus Infection Drug Market Forecast, By Disease Type 14.15.1. Upper Respiratory Tract Infections (URTIs) 14.15.2. Influenza 14.15.3. Bronchiolitis 14.15.4. Croup 14.15.5. Others(Pneumonia,Measles) 14.16. Rest of South America Respiratory Virus Infection Drug Market Forecast, By Drug Class 14.16.1. Nucleoside Analogs 14.16.2. Neuraminidase Inhibitors 14.16.3. Others(Ion Channel Blockers,Fusion Protein Inhibitors) 14.17. Rest of South America Respiratory Virus Infection Drug Market Forecast, By Disease Type 14.17.1. Upper Respiratory Tract Infections (URTIs) 14.17.2. Influenza 14.17.3. Bronchiolitis 14.17.4. Croup 14.17.5. Others(Pneumonia,Measles) 14.18. South America Respiratory Virus Infection Drug Market Attractiveness Analysis 14.18.1. By Drug Class 14.18.2. By Disease Type 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. AstraZeneca 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. AbbVie 15.3.3. Ablynx NV 15.3.4. ADMA Biologics 15.3.5. Alnylam Pharmaceuticals 15.3.6. Ark Biosciences 15.3.7. ImmunoVaccine Technologies, 15.3.8. Aviragen Therapeutics 15.3.9. Boehringer Ingelheim 15.3.10. Bavarian Nordic 15.3.11. Gilead Sciences 15.3.12. Johnson & Johnson 15.3.13. Kyowa Hakko Kirin 15.3.14. Mymetics Corporation 15.3.15. GlaxoSmithKline plc. 15.3.16. Teva Pharmaceutical 15.3.17. Vaxart

About This Report

Report ID 75722
Category Healthcare
Published Date Oct 2020
Updated Date
Contact Us